HU6


Liver-targeted prodrug of 2,4-dinitrophenol functioning as a controlled metabolic accelerator through mitochondrial uncoupling via adenine nucleotide translocase activation

A first-in-class controlled metabolic accelerator developed by Rivus Pharmaceuticals as a liver-targeted prodrug of 2,4-dinitrophenol, designed to exploit mitochondrial uncoupling for the treatment of metabolic dysfunction-associated steatohepatitis, obesity-related heart failure with preserved ejection fraction, and related cardiometabolic disorders while mitigating the systemic toxicity historically associated with the parent uncoupler.

Abstract

HU6 (dinifedriton; 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole; CAS 2231311-68-3) is a first-in-class controlled metabolic accelerator (CMA) developed by Rivus Pharmaceuticals as an oral prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP). The compound is designed to undergo hepatic bioactivation to release DNP within the liver, thereby increasing proton leak across the inner mitochondrial membrane via activation of the adenine nucleotide translocase (ANT) channel. This controlled mitochondrial uncoupling increases substrate oxidation, preferentially consuming hepatic and systemic fat stores while reducing reactive oxygen species production and preserving lean skeletal muscle mass. By restricting DNP release to the hepatic first-pass compartment and minimizing systemic peak concentrations, HU6 achieves a substantially wider therapeutic index than the parent uncoupler while retaining its metabolic efficacy.

The scientific foundation for HU6 derives from the seminal work of Perry et al. (2015), published in Science, demonstrating that a controlled-release mitochondrial protonophore (CRMP) formulation of DNP reversed diabetes, hypertriglyceridemia, hepatic steatosis, and liver fibrosis in rat models of metabolic syndrome and nonalcoholic steatohepatitis (NASH) without systemic toxicity [1]. This proof of concept was extended to dysmetabolic nonhuman primates by Goedeke et al. (2019), who reported that CRMP produced 20 to 30 percent reductions in fasting plasma triglycerides and low-density lipoprotein cholesterol with concurrent resolution of hepatic steatosis [2]. Rivus Pharmaceuticals was founded in 2019 to advance these findings into clinical development, selecting HU6 as the lead clinical candidate from a portfolio of controlled metabolic accelerator assets.

Three Phase 2 clinical trials have been completed or are in progress. The Phase 2a HuMAIN trial in 66 patients with obesity-related heart failure with preserved ejection fraction (HFpEF) met its primary endpoint of body weight reduction (2.86 kg versus placebo over 19 weeks), with fat-selective weight loss preserving skeletal muscle mass and producing significant improvements in left ventricular ejection fraction (3.76 percent) and end-systolic volume; results were published in JAMA Cardiology [4, 5]. The Phase 2 M-ACCEL trial in 228 patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F2 to F3 demonstrated statistically significant liver fat reductions of 27.0 to 31.2 percent versus 6.7 percent with placebo over 26 weeks, with approximately 50 to 58 percent of treated patients achieving the clinically meaningful threshold of 30 percent or greater liver fat reduction associated with MASH resolution and fibrosis improvement [6].

Across all three trials, HU6 demonstrated a favorable safety profile with no treatment-related serious adverse events in a cumulative safety database exceeding 500 patients. The most commonly reported treatment-emergent adverse events were flushing (32 percent in early trials, reduced in later formulations), diarrhea (25 percent), and palpitations (12 percent), with discontinuation rates due to adverse events below 5 percent. Gastrointestinal adverse event rates in the M-ACCEL trial were comparable to placebo (14 versus 16 percent). The compound is currently advancing through the AMPLIFY Phase 2 trial for MASH with plans for late-stage clinical development. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph